Skip to main content

Publications

Learn more about key research findings at Simpson Querrey Lung Institute for Translational Science (SQLIFTS) through these selected publications. SQLIFTS boasts two researchers, Navdeep Chandel, PhD and Richard Wunderink, MD, who regularly rank among the Clarivate list of most highly cited researchers.

Code repositories can be accessed here. See more publications on PubMed.

Insights into PASC 

An SQLIFTS study of patients with post-acute sequelae of COVID-19 (PASC) uncovered an association between severity of fibrosis and abundance of monocyte-derived alveolar macrophages (MoAMs) in the lungs. However, single-cell RNA sequencing revealed similar transcriptional profiles in MoAMs whether the patient's fibrosis resolved or worsened. These findings were published in Nature Immunology

New Blood Test for Severe Lung Disease

Investigators at SQLIFTS have developed a blood test to detect a proteomic signature identifying adults at high risk of developing severe lung disease. This study was published in the American Journal of Respiratory and Critical Care Medicine.

Aging and Transcript Length

In research published in Nature Aging, investigators at SQLIFTS discovered an association between biological aging and decreased expression of longer genes. These findings were further discussed in an article published in Trends in Genetics.

Understanding COVID-19

SQLIFTS investigators developed a model, published in Nature, to explain the unique pathobiology of COVID-19, and have identified secondary bacterial pneumonia as an important contributor to outcomes in patients with COVID-19 in a study published in the American Journal of Respiratory and Critical Care Medicine. SQLIFTS investigators also identified distinct T cell responses that correlate with outcome in SARS-CoV-2 pneumonia in a study published in Nature Immunology.

Insights into Lung Epithelial Cell Fate

In research published in Nature, SQLIFTS investigators determined that dysfunctional mitochondria disrupt cell differentiation during lung development. These findings could open new avenues for treatments of viral pneumonia or pulmonary fibrosis.

Cellular Metabolism and Lung Cancer

Investigators at SQLIFTS have made key contributions to our understanding of how cellular metabolism can be targeted as a treatment for lung cancer, in a study published in Nature.

Understanding Healthcare-Related Disparities

An SQLIFTS study published in Annals of Internal Medicine uncovered a systematic bias in the tests used to target patients for lung cancer screening which have led to important changes in policy.

Lung Transplantation for Patients With COVID-19

Foundational discoveries led by SQLIFTS investigators and published in Science Translational Magazine during the pandemic supported our decision to perform the first lung transplant for a patient dying from COVID-19. We have since performed more than 40 such procedures, reporting our findings nationally, including in JAMA.

Follow SQLIFTS on